top of page

UTHealth Houston
Department of Integrative Biology and Pharmacology 

2023
48acd04cff908f9ac284a66dfdc1a71e8dfd3bad_edited.jpg
  • Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. The 7th International Conference in Drug Discovery and Lead Optimization, San Francisco, CA, November 1-3 (2023)

  • Paitent-derived iPSCs in Cancer Modeling and Targeted Therapies. 2023 TTBA Symposium, Houston, TX, October 28-29 (2023)

TTBA_DFL.jpg
  • The oncogenic roles of mutant p53 in Li-Fraumeni syndrome associated cancers. Research Center for Cancer Biology. China Medical University, Taiwan., July 26, 2023 (Dr. Ruiying Zhao)

2023 Ruiying Talk.jpg
  • Patient-Derived iPSCs for cancer modeling and targeted Therapies, BIG-TCR program, SBMI, UTHealth Houston, Houston, TX, July 14, 2023

  • Possibility for patient-derived iPSCs in cancer modeling and targeted therapies, McGovern Medical School Research Retreat, Houston, TX, March 7, 2023

2023 Medical School Retreat.tif
  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, January 17, 2023

MDACC 2023 talk.jpg
Yang_Hsiang_rescue_his_father_from_a_tiger.jpg
2022
  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. Institue of Biomedical Sciences, Academia Sinica, Taiwan, November 21, 2022

  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. National Chung-Hsing University, Taichung, Taiwan, November 18, 2022

  • RB1/E2F Signaling: A Master Regulator of RNA Splicing. National Tsing Hua University, Hsinchu, Taiwan, November 17, 2022

  • RB1/E2F Signaling: A Master Regulator of RNA Splicing. Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, November 11, 2022

  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. 2022 ICCB & APOCB conference, Taipei, Taiwan, November 7, 2022

  • Possibilities for patient-derived iPSCs in cancer modeling and targeted therapies. 2022 International Conference on Advanced Biomedical Sciences ICABS Symposium, Taichung, Taiwan, November 5, 2022

  • Induced Pluripotent Stem Cells in Cancer Modeling and Drug Discovery. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, September 26, 2022

IMG_6884.JPG
IMG_6831.JPG
IMG_6783.JPG
IMG_6830.JPG
  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. 2022 UTHealth CPRIT CGC Workshop, March 7 2022

CGC workshop.tif
2021
2021%20OX%20stamp_edited.jpg
  • Patient-derived Induced Pluripotent Stem Cells in Cancer Modeling and Targeted Therapies. National Chung-Hsing University, Taiwan, December 16, 2021 (世界百大學校講者線上講座)

2020
rat 2020.png
  • RB1 tumor suppressor and osteosarcomagenesis. Sarcoma Research Group, Houston, TX, May 21 2020

  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies, St. John's University, New York, NY, October 28, 2020

  • Possibilities for Patient-derived iPSCs in Cancer Modeling and Targeted Therapies. National Chung-Hsing University, Taiwan, December 17, 2020 (世界百大學校講者線上講座)

NCHU talk.tif
2019
2019%2520pig-2_edited_edited.jpg
  • Dissecting and targeting p53-mutant osteosarcoma. Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, March 20, 2019.

  • Dissecting p53-mutant osteosarcoma with LFS iPSCs. Bone Club Meeting, Houston, TX, April 10, 2019.

  • Cancer disease modeling with induced pluripotent stem cells. UTHealth Human Genetics Center Seminar, Houston, TX, April 29, 2019.

  • Dissecting the biology and therapeutic vulnerabilities of RB1-mutant osteosarcoma using RB iPSCs. The 2019 Rolanette and Berdon Lawrence Bone Disease Program of Texas Scientific Retreat, Houston, TX, May 10, 2019

  • How to plan for successful academic career. 2019 The Texas Taiwanese Biotechnology Association (TTBA) symposium, Houston, TX, Jul 13,2019

HGC seminar.tif
MDACC talk-2.tif
2018
2018%20Dog_edited.jpg
  • Reprogramming to fit your scientific career. Cancer biology program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, Jan 18, 2018.

  • Modeling familial cancer syndrome with pluripotent stem cells. UTHealth Center for Precision Health (CPH) Seminar in Precision Medicine, Houston, TX, April 20, 2018.

  • Dissecting cancer etiology in a dish. UTHealth Department of Biochemistry and Molecular Biology Seminar, Houston, TX, May 14, 2018.

  • Dissecting cancer etiology in a dish. A Symposium in Memory and Celebration of Ihor R. Lemischka, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, June 14, 2018.

  • Human pluripotent stem cells for modeling cancer. ThermoFisher Scientific Houston Stem Cell Symposium, Houston TX, September 11, 2018.

  • Dissecting osteosarcoma etiology in a dish. Sarcoma Research Group, Houston, TX, October 18, 2018.

ThermoFisher talk.tif
Lemischka talk.tif
CPH talk.tif
2017
2017%20chicken-3_edited.jpg
  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, March 3, 2017.

  • Dissecting cancer etiology in a dish. Dr. Zhongming Zhao’s lab meeting. School of Biomedical Informatics, UTHealth, Houston, April 5, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Department of Molecular Cellular Oncology and Center for Biological Pathways Seminar Series, The University of Texas MD Anderson Cancer Center, Houston, May 3, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan, June 23, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, June 27, 2017.

  • Dissecting cancer etiology in a dish. Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan, June 28, 2017.

  • Pluripotent stem cells- opportunities to model familial cancer syndromes. Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, July 4, 2017.

  • Dissecting cancer etiology in a dish. Umeå University, Umeå, Sweden, September 15, 2017.

MDACC MCO talk.tif
1060628李東芳博士(林立元教授主持).tif
NTU seminar.tif
2016
2016 Monkey.jpg
  • Modeling Li-Fraumeni syndrome with induced pluripotent stem cells. Dr. Lisa L Wang’s lab meeting. Texas Children’s Hospital, Houston, April 23, 2016

  • Modeling Li-Fraumeni syndrome with induced pluripotent stem cells. Center for Stem Cell & Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, UTHealth, Houston, May 9, 2016.

  • Modeling Li-Fraumeni syndrome with pluripotent stem cells. Society of Chinese Bioscientists in America (SCBA)-Texas Chapter Faculty Club, Houston, September 23, 2016.

  • Modeling cancer with pluripotent stem cells, CMU-MDACC visiting meeting. Department of Molecular Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, December 12, 2016.

bottom of page